North America Meglitinide Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The North America Meglitinide Market is segmented by Geography (United States, Canada, and the Rest of North America). The report offers the value (in USD million) and Volume (in Unit million) for the above segments.

Home right-chevron-icon Industry Reports right-chevron-icon Healthcare right-chevron-icon Diabetes Drugs & Devices right-chevron-icon North America Meglitinide Market

North America Meglitinide Market Size

NAMEGL
Study Period: 2018 - 2028
CAGR: > 2 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and it's growth?

North America Meglitinide Market Analysis

The North America Meglitinide Market is expected to register a CAGR greater than 2% over the forecast period.

In North America, the United States is having the highest number of COVID cases with 82 million by April 2022, the country also registered the highest death rate. According to the Diabetes Voice article published in May 2020, close to 40,000 deaths are people with diabetes. In the North American region diabetes patients are more concerned about stocking up the monitoring and managing devices due to this the market increased during these years.

The North American region had witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people.​ Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates.

Meglitinides are a type of non-sulfonylurea insulin secretagogues with a fast onset and short duration of action. They stimulate glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes, who have chronically high blood sugar levels.

The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

This is driving the demand for Meglitinides in North America, thereby driving the market in focus during the forecast period.​

North America Meglitinide Industry Segmentation

The North America Meglitinide Market is expected to register a CAGR greater than 2% over the forecast period. The North America Meglitinide Market is segmented by Geography (United States, Canada, and the Rest of North America). The report offers the value (in USD million) and Volume (in Unit million) for the above segments.

Drug
Meglitinides (Value and Volume, 2022-2027)
Geography (Value and Volume, 2022-2027)
United States
Canada
Rest of North America

Report scope can be customized per your requirements. Click here.

North America Meglitinide Market Trends

This section covers the major market trends shaping the North America Meglitinide Market according to our research experts:

Rising Diabetes Prevalence in North America Region

According to the National Diabetes Statistics Report 2021, approximately 37.3 million people, or approximately 11.3% of the US population, have diabetes. People who are overweight are more likely to develop prediabetes, which can progress to Type 2 diabetes, putting them at risk for complications, acute and long-term complications, and death. Obesity, an unhealthy diet, and a sedentary lifestyle are all contributing to an increase in newly diagnosed Type 1 and Type 2 diabetes cases. The increased prevalence of diabetic patients and global healthcare expenditure are indicators of a greater proclivity for diabetic drugs. Type 2 diabetes (T2D) is becoming more common and is linked to an increased risk of cardiovascular and renal disease. Meglitinides are oral medications used to treat Type 2 diabetes in conjunction with lifestyle changes. They work by stimulating insulin release from pancreatic beta cells, which lowers blood glucose levels. Meglitinides do not work in people with type 1 diabetes because their action is dependent on the presence of functioning Beta cells.

NApop

The United States is Expected to Dominate the North America Meglitinides Market.

This class of drugs, also known as nonsulfonylurea secretagogues, is relatively new in comparison to the sulfonylureas (chlorpropamide [brand name Diabinese], glyburide [DiaBeta, Glynase, Micronase], glipizide [Glucotrol], glipizide extended-release [Glucotrol XL], and glimepiride [Amaryl] Meglitinides work in a similar way to sulfonylureas, but with a few key differences.

Meglitinides, for example, bind to the sulfonylurea receptor in beta cells (pancreatic insulin-producing cells) but at a different part of the receptor than sulfonylureas do. Meglitinides' interaction with the receptor is not as "tight" as sulfonylureas', resulting in a much shorter duration of action and a higher blood glucose level required before the drugs produce insulin secretion from the pancreas. In the United States, two meglitinides are currently available: repaglinide (Prandin) and nateglinide (Starlix). Both are approved for use in people with Type 2 diabetes, both alone and in combination with other oral diabetes medications. Meglitinides' main effect is to lower after-meal blood glucose levels, which results in a lower HbA1c (an indicator of blood glucose control over the previous 2–3 months).

Owing to the aforementioned factors the market is expected to grow during the forecast period.

NAMEG

North America Meglitinide Industry Overview

The Meglitinides market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis having a global market presence and the market is highly competitive due to generic drugs manufacturers' presence.

North America Meglitinide Market Leaders

  1. Novo Nordisk

  2. Glenmark

  3. Novartis

  4. KISSEI

  5. Biocon

*Disclaimer: Major Players sorted in no particular order

NAMEGL.png

North America Meglitinide Market News

  • In June 2020, Biocon Ltd and DKSH announced that Biocon’s subsidiary, Biocon Pharma Limited, and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma’s generic formulations in Singapore and Thailand. Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology, and immunology, which will be sold under Biocon’s brand in Singapore and Thailand.
  • In June 2019, Kissei Pharmaceutical Co., Ltd. announced that the GLUBES Combination OD Tab., which is the new orally disintegrating dosage form of the GLUBES Combination Tab. (generic name: mitiglinide calcium hydrate/voglibose), will be launched in Japan, for the treatment of diabetes. GLUBES Combination Tab. is an oral combination drug comprising the rapid-acting insulin secretagogue mitiglinide, which was created by Kissei, and the postprandial hyperglycemia agent voglibose.

North America Meglitinide Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 Drug

      1. 5.1.1 Meglitinides (Value and Volume, 2022-2027)

    2. 5.2 Geography (Value and Volume, 2022-2027)

      1. 5.2.1 United States

      2. 5.2.2 Canada

      3. 5.2.3 Rest of North America

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016 - 2027)

    2. 6.2 Type-2 Diabetes Population (2016 - 2027)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk

      2. 7.1.2 Novartis

      3. 7.1.3 Glenmark

      4. 7.1.4 Boehringer Ingelheim

      5. 7.1.5 Biocon

      6. 7.1.6 Kissei Pharmaceuticals

    2. 7.2 Company Share Analysis

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

North America Meglitinide Market Research FAQs

The North America Meglitinide Market is studied from 2018 - 2028.

The North America Meglitinide Market is growing at a CAGR of >2% over the next 5 years.

The North America Meglitinide Market is valued at 953 Million USD in 2018.

The North America Meglitinide Market is valued at 1071 Million USD in 2028.

Novo Nordisk, Glenmark, Novartis, KISSEI, Biocon are the major companies operating in North America Meglitinide Market.

North America Meglitinide Industry Report

Statistics for the 2023 North America Meglitinide market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Meglitinide analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!